USDTL Develops Assay to Detect Zolpidem (Ambien®) in Fingernails and Hair
Showing: hair testing
Des Plaines, IL – United States Drug Testing Laboratory, Inc. (USDTL), a forensic laboratory specializing in drug and alcohol testing using advanced specimens, has released a new assay to detect zolpidem (Ambien®) use in fingernail and hair specimens. Previously available only in urine and oral-fluid specimens, zolpidem testing in fingernails and hair offers forensic drug testing professionals new, powerful tools to meet their drug testing needs.
Since its approval in 1993 for the treatment of insomnia, zolpidem has become one of the most popular and most prescribed sleep aids. Zolpidem is a sedative-hypnotic medication that affects the same areas of the brain as benzodiazepines. In 2011, 39 million prescriptions for zolpidem products were written in the United States. 
Zolpidem use carries some risks of harm, especially when taken in combination with other substances. The number of emergency department visits related to zolpidem grew by 136% from 2004 (12,792) to 2011 (30,149).  Other substances were involved in 57% of those ED visits, including benzodiazepines (26%), narcotic pain relievers (25%), and alcohol (14%). 
The development of zolpidem testing is driven by USDTL’s ongoing commitment to be a leader in substance abuse and alcohol detection. Zolpidem testing in fingernails and hair will be available on October 1st, 2014.
USDTL has made significant breakthroughs in detecting alcohol and other substances of abuse. They offer a wide range of testing services and specialize in hard to detect substances of abuse, customized assays, and advanced drug testing specimens.
1. IMS, Vector One: National (VONA) and Total Patient Tracker (TOT). Year 2011. Extracted June 2011.
2. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (May 1, 2013). Emergency Department Visits for Adverse Reactions Involving the Insomnia Medication Zolpidem. Rockville, MD.
3. Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.https://www.usdtl.com/blog/usdtl-develops-assay-to-detect-zolpidem-ambien-in-fingernails-and-hair
Pot Plans: Efforts Surge in Congress to Reform Marijuana Laws
Read more: http://swampland.time.com/2013/02/06/pot-plans-efforts-surge-in-congress-to-reform-marijuana-laws/#ixzz2KiIw4pXr
Colorado Legislature Gears Up to Debate Drugged Driving Limits:
Is Pot Smoking a Stroke Trigger?
For Release Immediately
December 31st, 2012
DES PLAINES, IL— HairStat® / NailStat®Improved Cutoffs — Today, United States Drug Testing Laboratories, Inc. announced that they will introduce lower substances of abuse screening and confirmation cutoffs for hair and nail specimens.
Positive Customer Impact
Many customers have already benefited from using USDTL as a laboratory that can customize drug testing to suit their needs. The improvement of the cutoffs means that customers can now have a wider range of detection for certain substances of abuse, and can be assured that they are receiving positive drug screen confirmations not currently available at market place. The breadth and sensitivity of the profiles make these tests more effective.
HairStat® / NailStat® Availability
These improvements in HairStat and NailStat are driven by USDTL’s ongoing commitment to be a leader in alcohol and substances of abuse detection. These cutoffs will be effective for hair and nail specimens received at USDTL on or after January 2nd, 2013.
Established in 1991 as a specialty drug testing facility, United States Drug Testing Laboratories, Inc. quickly became a leader in the industry. They have made significant breakthroughs by developing procedures to effectively use specimens to diagnose alcohol and substance misuse and abuse. They offer a wide range of testing services and specialize in hard to detect substances of abuse and customized assays.
For more information please visit http://www.USDTL.com
USDTL, HairStat®, NailStat® are trademarks of Unites States Drug Testing Laboratories, Inc. in the United States and/or other countries.
For more information, press only:
Marketing Communications Manager
For more information on HairStat® or NailStat®:https://www.usdtl.com/blog/laboratory-announces-improvements-in-testing-hair-and-nail-for-substances-of-abuse
Q: I received a report that says “REJECTED” and “Profile not indicated- fax request to lab”. What does that mean? Has the specimen been destroyed? What should I do?
A: One piece of information that must be present on the Requisition Form is the Test Profile Requested. The lab is not allowed to pick and choose which panels to run on your behalf. We must obtain that information from the client in writing.
If the requisition form does not indicate which test to run, we reject the specimen with a request for the client to notify USDTL which profile to run on the specimen. You may notify the lab of the test profile you desire by fax or email. Remember to include multiple pieces of identification on the request. One fail-safe and quick way to notify the lab of which test to run is to note the desired profile on your fax copy and fax that over to the lab.
These specimens are retained for at least one week. Specimen requests not resolved within one week are scheduled for destruction along with the week-old negative specimens. One alternative to consider is the selection of a “Default Profile”. Having this information documented and on file at the laboratory allows the laboratory to assign a default profile when one is not indicated on the Requisition Form.https://www.usdtl.com/blog/ask-our-toxicologists-hair-testing
- Identifying the Indiscernible Isotonitazene (iso)
- Gabapentin, An Emerging Threat in Today’s Opioid Epidemic
- What We Know About CBD
- Kratom Abuse – an Analytical Study on Kratom calls to Poison Control Centers from 2011-2017
- Kratom and its Controversial Threat to Public Health
- Gabapentin Abuse
- USDTL’s Aileen Baldwin Coauthors Recent Studies of Prenatal Alcohol Exposure
- The Development of Alcohol Use Disorder: The Overlooked Epidemic